6/26/2025

Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that Viatris Inc. ("Viatris"), has secured regulatory approval from China's National Medical Products Administration (NMPA) for YUPELRI® (revefenacin) inhalation solution, the first once–daily nebulized long–acting muscarinic antagonist (LAMA) approved for maintenance treatment of chronic obstructive pulmonary disease (COPD) in China.

Source: Yahoo

6/26/2025

Theravance Biopharma, Inc. announced that Viatris Inc. , has secured regulatory approval from China?s National Medical Products Administration for YUPELRI inhalation solution, the first once-daily...

Source: Finnhub

6/10/2025

Phathom Pharmaceuticals, Inc.'s FDA-granted exclusivity for Voquezna positions it as a GI market leader. Click here to find out why PHAT stock is a Buy.

Source: SeekingAlpha

6/6/2025

Theravance Biopharma Inc: * THERAVANCE BIOPHARMA - THERAVANCE AND MYLAN ENTERSETTLEMENTAGREEMENT WITH EUGIA - SEC FILING * THERAVANCE BIOPHARMA INC - SETTLEMENT RESOLVES...

Source: Finnhub

6/3/2025

Theravance to sell its remaining Trelegy royalty interest to GSK for $225M, with shares jumping 22% on the deal's announcement.

Source: Yahoo

6/2/2025

Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that it has entered into a definitive agreement to sell its remaining royalty interest in net sales of Trelegy Ellipta ("Trelegy") to GSK (NYSE: GSK) for $225 million in cash.

Source: Yahoo

5/21/2025

We think intelligent long term investing is the way to go. But that doesn't mean long term investors can avoid big...

Source: Yahoo

5/13/2025

Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the H.C. Wainwright 3rd Annual BioConnect Investor Conference in New York City at NASDAQ Tuesday, May 20 at 10:30 AM EDT (7:30 AM PDT / 3:30 PM IST) and will be hosting in-person meetings with the investment community at the conference.

Source: Yahoo

5/10/2025

Theravance Biopharma, Inc. (NASDAQ:TBPH) Q1 2025 Results Conference Call May 8, 2025 5:00 PM ETCompany ParticipantsRick Winningham - Chief Executive...

Source: SeekingAlpha

5/9/2025

TBPH reports weaker-than-expected first-quarter 2025 results. Collaboration revenues from Viatris rise year over year.

Source: Yahoo

5/9/2025

Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced presentation of analyses of its previous Phase 3 program evaluating ampreloxetine, an investigational medicine for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) at the International MSA Congress, taking place May 9-11 in Boston, Massachusetts.

Source: Yahoo

5/9/2025

Theravance Biopharma, Inc. announced presentation of analyses of its previous Phase 3 program evaluating ampreloxetine, an investigational medicine for the treatment of symptomatic neurogenic...

Source: Finnhub

5/9/2025

Theravance Biopharma Inc (TBPH) reports a robust 6% increase in net sales and significant hospital channel momentum, while navigating increased expenses and litigation issues.

Source: Yahoo

5/8/2025

Theravance Bio (TBPH) delivered earnings and revenue surprises of -54.55% and 4.20%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Source: Yahoo

5/8/2025

Theravance Biopharma First Quarter 2025 Financial Results and Business Update May 8, 2025 THERAVANCE BIOPHARMA®,...

Source: Finnhub

5/8/2025

Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial and operational results for the first quarter of 2025.

Source: Yahoo

4/28/2025

Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that analyses of the initial Phase 3 program of ampreloxetine (Studies 169 and 170) will be presented at the International MSA Congress, taking place May 9-11, 2025, in Boston, Massachusetts. These analyses support the Company's understanding of ampreloxetine's highly selective mechanism of action and potential to address symptoms of neurogenic orthostatic hypotension (nOH) in patients with multip

Source: Yahoo

4/24/2025

Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its first quarter 2025 financial results and provide a business update after market close on Thursday, May 8, 2025. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm EDT (2:00 pm PDT/10:00 pm IST) that day.

Source: Yahoo

4/7/2025

Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced new analyses from its previous Phase 3 program evaluating ampreloxetine, an investigational medicine for the treatment of symptomatic neurogenic orthostatic hypotension (nOH). Both analyses were presented as platform presentations at the 77th Annual Meeting of the American Academy of Neurology (AAN) Meeting, taking place April 5-9, 2025, in San Diego, California. Findings support ampreloxetine's h

Source: Yahoo

3/28/2025

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Source: Yahoo